Congress Asset Management Co. Boosts Stake in Johnson & Johnson $JNJ

Key Points

• Congress Asset Management Co. increased its Johnson & Johnson stake by 599.6% in the third quarter, adding 32,133 shares to own 37,492 shares valued at approximately $9.93 million.
• Institutional investors own 69.55% of J&J, while analysts maintain a “Moderate Buy” consensus with an average price target of $276.22.
• J&J reported 6.6% year-over-year revenue growth and raised its 2026 earnings guidance, but investors continue to monitor biosimilar competition, patent expirations, MedTech recovery and talc litigation risks.

Congress Asset Management Co. increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 599.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,492 shares of the company's stock after purchasing an additional 32,133 shares during the quarter. Congress Asset Management Co.'s holdings in Johnson & Johnson were worth $9,926,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. National Pension Service raised its position in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after acquiring an additional 3,133 shares during the period. Elefante Mark B boosted its holdings in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after acquiring an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC increased its position in Johnson & Johnson by 76.1% during the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company's stock valued at $3,697,000 after purchasing an additional 6,539 shares during the period. Finally, Gradient Investments LLC raised its holdings in Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent analyst reports. HSBC boosted their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $276.22.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support remains strong. Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 11% upside from the referenced price. RBC Capital also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Investors are increasingly viewing JNJ as a growth story. Recent coverage highlighted second-quarter revenue growth of 6.6%, adjusted EPS growth of 4.7% and an increase in full-year 2026 guidance. This contrasts with Pfizer, whose lower valuation reflects expectations for declining earnings, helping explain why JNJ commands a much higher earnings multiple. Johnson & Johnson Is Becoming a Growth Stock
• Positive Sentiment: Pipeline progress adds longer-term upside. JNJ’s Tecvayli-Talvey combination produced substantial reductions in progression and mortality risk in a Phase 3 multiple-myeloma study. Separately, two-year data for oral psoriasis treatment ICOTYDE showed durable skin clearance and consistent safety, supporting its commercial potential. 2026 Cancer Treatment Advances ICOTYDE Long-Term Psoriasis Data
• Neutral Sentiment: A pricing agreement may reduce an overhang before earnings. Coverage said a pricing pact has eased investor concerns ahead of the company’s next results, though the precise financial impact and durability of the agreement remain important items to monitor. Johnson & Johnson Pricing Pact Eases Overhang
• Negative Sentiment: Risks temper the bullish case. Analysts and investors continue to assess biosimilar competition, a slower MedTech recovery, the coming pharmaceutical patent cliff and ongoing talc litigation. JNJ’s premium valuation leaves less room for execution or earnings disappointments. Johnson & Johnson Dividend Royalty Status

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $258.25 on Thursday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $622.35 billion, a PE ratio of 29.92, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. The stock's fifty day simple moving average is $265.71 and its two-hundred day simple moving average is $248.78. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. The business's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's payout ratio is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.